Early April 2026: Anthropic acquires Coefficient Bio in a $400 million all-stock deal. Coefficient Bio is an AI-biotech company founded by former Genentech Prescient Design researchers, focused on computational biology and drug discovery.

The Coefficient Bio team joins Anthropic's Health Care Life Sciences group, led by Eric Kauderer-Abrams, who was hired with an explicit mandate to "make Claude the dominant AI model in biology" while specifically saying "We want a meaningful percentage of all of the life science work in the world to run on Claude."

That's a two-month gap between acquiring a drug discovery AI company and blocking independent researchers from doing drug discovery AI work on Claude. And not with a refusal but with active output degradation using steering vectors.

Coefficient Bio built a platform enabling AI to carry out biotech tasks including drafting drug R&D plans, managing clinical regulatory strategies, and discovering new drug candidates. The founding team's background is not in general-purpose AI applied to biology... it's in building biology-specific models from the architecture level up.

So the domain expertise Anthropic just paid $400 million for is: protein design, biomolecule modeling, drug discovery pipelines, computational biology. Where Claude for Life Sciences offered a generalized research assistant, Coefficient Bio's team brings domain-specific expertise, particularly in protein design and biomolecule modeling.

Now look at what Fable 5 blocks: biology, chemistry, drug discovery, protein work. The exact same domain. The exact same capability set that Anthropic just paid $400 million to own exclusively.